Clinical trials: COMBO Condition
Dental Pain
Dental Pain Study of Analgesics in Patients Undergoing Molar Removal
Accessing the efficacy and safety of pregabalin when used alone and in combo with acetaminophen in a dental pain model. To test whether pre-operative dose of pregabalin increases the time to significant post-operative pain (NRS ≥…
- Trial name
- NVK009-0001 (NCT03652818)
- Testing
- Pre-Op pregabalin, Post-Op pregabalin
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Nevakar, Inc.
Hypertension
Antihypertensive Efficacy of Fixed Combination Drug
Treatment and control of hypertension is still insufficient. About 50% of the patients remain uncontrolled. Lack of compliance with discontinuation of drug treatment is an important reason for not achieving blood pressure.
- Trial name
- NCT01211314
- Testing
- Lercanidipine/enalapril fixed combination
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Meir Medical Center
Hypoxia, Esophageal Cancer
COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. This is particularly true for obese patients, who have a higher incidence of hypoxia.
- Conditions
- Hypoxia, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06796764
- Testing
- the COMBO Endoscopy Oropharyngeal Airway Group, Regular Nasal Cannula
- Where
- 3 sites in China
- Volunteers
- 580 people
- Sponsor
- Zhejiang University
Chronic Pain, Back Pain
Combining Mechanisms for Better Outcomes (COMBO)
To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities as compared to conventional SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.
- Trial name
- COMBO (NCT03689920)
- Testing
- Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
- Where
- 15 sites in United States
- Volunteers
- 174 people
- Sponsor
- Boston Scientific Corporation
Multiple Myeloma
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
This will be a multi-center, open label, expanded treatment protocol of panobinostat, bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT02204553
- Testing
- Panobinostat
- Where
- 27 sites in United States
- Sponsor
- Novartis Pharmaceuticals
IBS - Irritable Bowel Syndrome, Depression, Anxiety
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
This study aimed to assess the impact of consumption of COMBO, a combination product of two Bifidobacterium longum strains, on stress, mood and bowel symptoms in adults with Irritable Bowel Syndrome (IBS).
- Trial name
- IBS (NCT04422327)
- Testing
- Probiotic capsule
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- PrecisionBiotics Group Ltd.
Metastatic Breast Cancer
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)].
- Trial name
- VERU-024 (NCT05065411)
- Testing
- Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- Where
- 30 sites in United States
- Volunteers
- 5 people
- Sponsor
- Veru Inc.
SARS-CoV-2, Influenza A
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites.
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
- Trial name
- ITAP1489 (NCT05787444)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B
- Where
- United States
- Volunteers
- 1,081 people
- Sponsor
- LumiraDx UK Limited
Type 2 Diabetes
A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes
This is a randomised, double-blind, four-period crossover euglycaemic clamp trial in subjects with type 2 diabetes. Each subject will be randomly allocated to one of four treatment sequences.
- Trial name
- NCT05373212
- Testing
- Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Adocia
Influenza
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza.
- Trial name
- COMBO 1 (NCT04327791)
- Testing
- Baloxavir
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Bassett Healthcare
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea…
- Trial name
- NCT00662740
- Testing
- FDC tiotropium / salmeterol, Salmeterol, Tiotropium (Spiriva®)
- Where
- 72 sites in United States, Austria and 16 more
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach…
- Trial name
- NCT00280540
- Testing
- Valsartan/Hydrochlorothiazide
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Novartis
Breast Cancer, Chemotherapy Effect
Home-Combo: an Online Home-based Combined Exercise Intervention for Women With Breast Cancer
Background. Chemotherapy drugs carry many side effects that may hinder the functional performance of women with breast cancer (BC). Chemoresistance can lead to treatment failure.
- Trial name
- NCT06429189
- Testing
- Home-based combined exercise program with self-selected intensity
- Where
- Portugal
- Volunteers
- 98 people
- Sponsor
- Grupo Lusófona
Colorectal Cancer
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
The primary objective of the Phase I part of the study is to determine the recommended dose of capecitabine to be administered in combination with ZD1839 250 mg orally once daily in subjects with advanced or metastatic colorectal…
- Trial name
- NCT00242788
- Testing
- Gefitinib and capecitabine
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Metastatic Triple Negative Breast Cancer
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
To compare the following: 1. The efficacy of sabizabulin monotherapy to sacituzumab govitecan-hziy monotherapy 2. The efficacy of sacituzumab govitecan-hziy/sabizabulin combination therapy to sacituzumab govitecan-hziy…
- Trial name
- VERU-111 (NCT05008510)
- Testing
- Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy Combo
- Sponsor
- Veru Inc.
Nausea, Vomiting
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous…
- Trial name
- NCT00314743
- Testing
- Ondansetron, Dexamethasone, Aprepitant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Adenoidal Disorder, Tonsillitis
Study on the Efficacy and Safety of a Device for Post-op Recovery in Pediatric Adenectomy/Adenotonsillectomy.
The objective of this prospective pre-market interventional clinical study is to evaluate the efficacy and safety of the medical device Munatoril® Aerosol Combo in its different modalities of use, through the analysis of clinical…
- Conditions
- Adenoidal Disorder, Tonsillitis, Otorhinolaryngologic Diseases, Nasal Disease
- Trial name
- NCT06478433
- Testing
- Munatoril Aerosol Combo, Iperclenny
- Volunteers
- 90 people
- Sponsor
- Pharmaluce srl
Graves' Disease
Graves' Disease Remission Study: MycoMeth Combo
A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.
- Trial name
- 3M-RGD (NCT06068179)
- Testing
- Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg
- Where
- China
- Volunteers
- 205 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Coronary Restenosis
EGO-COMBO Clinical End-point Extension Study Beyond 36 Months
In this study, the safety and efficacy of COMBO TM stent beyond 36 months are assessed, in particular the occurrence of late stent thrombosis and late loss catch-up (restenosis).
- Trial name
- NCT02263313
- Testing
- EGO-COMBO group
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The University of Hong Kong